Anavex Execs Buy Shares Amid FDA Hype: CFO & CEO Add 12,500 & 125,000 Units as Alzheimer’s Trial Awaits Verdict
Insider buying shows confidence in Anavex’s Alzheimer’s drug as the FDA seeks trial data—expert analysis explains why executives are buying shares.
3 minutes to read
